Seelos Therapeutics (SEEL)

[ALERTS100%to10000%GAIN]

About the Merger

In connection with the merger, Apricus effected a reverse split of its common stock. Following the reverse stock split and closing of the merger, there are approximately 6,221,822 shares of the combined company’s common stock outstanding, subject to rounding up any fractional shares as a result of the reverse split, with pre-merger Seelos shareholders owning approximately 85% and pre-merger Apricus shareholders owning approximately 15%. Cash, cash equivalents and short-term investments for the combined company at the closing were approximately $18 million, prior to payment of transaction costs.